Fractyl Health Q2 2025 net loss $27.9M; $23M offering extends cash runway into 2026

FRACTYL HEALTH, INC.

2025-Q2 EPS reported -$1.05 vs consensus -$0.37 ▼ miss (-185.9%)

Net loss for Q2 2025 was $27.9 million, compared to $17.2 million in Q2 2024, driven by higher R&D spending and non-cash changes.
Completed $23 million underwritten public offering in August 2025, with potential additional $46 million from warrants.
Cash and cash equivalents were $22.3 million as of June 30, 2025; post-offering cash runway extends into 2026.
Positive 3-month REVEAL-1 Cohort data: 12 of 13 participants maintained weight after GLP-1 discontinuation with Revita.
Enrollment completed for REMAIN-1 Midpoint Cohort (45 participants); 3-month randomized data expected September 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.